Skip to main content
Uncategorized

Endor has launched to market a cosmetic treatment based on its discoveries on skin regeneration

By 29 de April de 2015November 18th, 2020No Comments
< Back to news
From left to right, Judith Sendra, director of R&D, and Joaquim Querol, CEO of Endor. (Photo: Daniel Portales, PCB).
 29.04.2015

Endor has launched to market a cosmetic treatment based on its discoveries on skin regeneration

The start-up Endor Nanotechnologies, based at the Parc Científic de Barcelona, has launched to market a cosmetic treatment that has been called Y.en. This is the first application of an innovative technology developed by the biotech for dermal tissue regeneration in damaged skin in cases of poor prognosis and for which there is no specific treatment.

 

Y.en is one of first nanotech compounds authorized by the European Commission and Endor has covered all stages of the product, from basic research to industrial production of nanomaterials and subsequent launch of the brand, which is already being commercialized in renowned clinics and specialized stores.

As a result of the development of an innovative R&D program in nanomedicine, Endor has discovered how to activate the mechanism that encourages cell movement, reproduction and nourishment- three basic aspects cell life depends on, and adaptation of this technology to the regeneration of skin tissue has become the first initiative that the start-up will bring to the end-user.

“Y.en is a revitalizer of the cells of the dermis and epidermis which acts on those inner qualities that most influence the external appearance of the skin. It does this through an active principle developed with nanoparticles” Joaquin Querol, CEO and co-founder of the company explains.

“This is one of the first experiences worldwide whereby a compound based on nanotechnology shows its effects on the human body. This technology could be very helpful in the short term to treat skin lesions of patients receiving chemotherapy, one of the most severe and painful side effects that 50% of cancer patients are currently exposed to, and for which there is no specific treatment at present, “said Querol.

 

Nanotechnology  applied to oncology and dermatology

Endor Nanotechnologies is a nanomedicine company specializing in the development of healthcare products using nanotechnology. Its main area of research is the development of antitumor drugs. Led by Joaquin Querol, the company was created in 2006 and features two other co-founding partners: Judith Sendra, current director of R & D and Javier Fernández, CFO.

The company is one of a kind among the start-ups dedicated to research in nanomedicine. Its business model is based on advanced research (allocating between 60 and 70% of its budget to research) from which it creates innovative products that reach the end-user and improve people´s quality of life of people.

Its funding comes mainly from the sales of its products and 100% of the social capital continues to be in the hands of the entrepreneurial team. “The goal of short-term products such as cosmetics is to finance with its own resources long-term projects such as our cancer research programs. In the mid-term we expect close partnership agreements with major pharmaceutical companies to bring medical treatments to patients, and complement its funding with venture capital so as to address the clinical development of these programs”, says the biotech´s CEO.

Its first compound for pancreatic cancer is already at the same level of efficacy in the animal model as current chemotherapy but without causing any side effects. The company plans to start the clinical phase of the drug by 2017.

Endor was one of the first companies to be accepted to form part of the register that the European Commission started in 2013 as a result of new and demanding regulations involving European nanomedicine companies that plan to market products yielded by their research for cosmetic purposes. The start-up was also awarded the 2014 Senén Vilaró Award to the best innovative company.